24 May 2019 - Governments are working on a drug pricing transparency deal at the World Health Organization’s (WHO) annual assembly, but activists said on Thursday they fear crucial costs may be left out, enabling pharmaceutical firms to keep prices high.

Campaigners say some drugs are exorbitantly priced, even though they are often developed with public funding, and health providers often pay far too much, since governments negotiate prices without knowing what the treatment cost to develop.

“We are not talking about a revolution for the sector, we are talking about just setting a fair price according to what has been invested,” said Patrick Durisch at Public Eye, a Swiss non-profit organisation. “Why should it be different for the pharmaceutical industry than in other sectors?”

Read Reuters article